Results 121 to 130 of about 11,456 (188)

BIOANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF CANAGLIFLOZIN IN HUMAN PLASMA BY LIQUID CHROMATOGRAPHY–TANDEM MASS SPECTROMETRY: CANAGLIFLOZIN IN HUMAN PLASMA BY LC-MS/MS

, 2019
Objective: A validated liquid chromatography–tandem mass spectrometry (LC–MS/MS) method was developed for canagliflozin in human plasma along with stability studies.
BASAVESWARA RAO MV, DEEPAN T, DHANARAJU MD   +2 more
core  

Urinary dipstick findings and UTI risk with SGLT2 inhibitors: a post-hoc analysis of the CANVAS and CREDENCE trials. [PDF]

Nephrol Dial Transplant
Doi Y, Hamano T, Fukuda-Doi M, Isaka Y.
europepmc   +1 more source

Association between different sodium-glucose co-transporter 2 inhibitors and the risk of dementia: a network meta-analysis. [PDF]

Front Endocrinol (Lausanne)
Meng Z, Wu H, Miao Y, Qi W, Sha M.
europepmc   +1 more source

Preliminary Evaluation of SGLT2 Inhibitors in Human Bladder Cancer T24 Cells. [PDF]

Biomedicines
Szachniewicz M, Baran M, Gagat M, Hałas-Wiśniewska M.   +3 more
europepmc   +1 more source

Canagliflozin treatment of a horse with hyperinsulinemia, including pharmacokinetic analysis of different dosing protocols: a case report. [PDF]

Front Vet Sci
Burbidge C, White K, Armstrong K, Rosa B.   +3 more
europepmc   +1 more source

AMPK-OXSR1 signaling coordinates proximal tubular sodium transport and is modulated by canagliflozin. [PDF]

Front Endocrinol (Lausanne)
Nakamura M, Seki G, Satoh N, Takagi M, Mizuno T, Tsukada H, Horita S, Sato Y, Kume H, Nangaku M.   +9 more
europepmc   +1 more source

The effect of canagliflozin on hippocampal dendrite morphology in a model of Alzheimer's disease induced by intracerebroventricular injection of streptozotocin. [PDF]

Brain Struct Funct
Yazi S, Ozen B, Buldu B, Yalcin E, Karakose O, Cakmak O, Somunkiran S, Yananli HR, Sehirli US, Kirazli O.   +9 more
europepmc   +1 more source

Genetics of Response to Canagliflozin (GRC) Study: Rationale, Design, and Pharmacodynamic Responses. [PDF]

Clin Transl Sci
Montasser ME, Bargal SA, Streeten EA, Whitlatch HB, Yazdi ZS, Sirody J, Kiplagat R, Beshara M, O'Connell JR, Taylor SI, Beitelshees AL.   +10 more
europepmc   +1 more source

The Effect of Canagliflozin Dose on Renal and Cardiovascular Outcomes in Type 2 Diabetes and High Cardiovascular Risk. [PDF]

Diabetes Obes Metab
Elenjickal EJ, Baroz F, Boileau P, Tsoukas MA, Sharma A, Mavrakanas TA.   +5 more
europepmc   +1 more source

Weight loss by sodium-glucose co-transporter 2 inhibitor canagliflozin is followed by rebound in db/db mice but maintained in fat-fed mice via circadian rises in body temperature and locomotor activity. [PDF]

J Physiol Sci
Wang L, Han W, Zhantleu D, Banno S, Rakhat Y, Kulzhanova N, Yussupov A, Iwasaki Y, Nakata M, Yabe D, Seino Y, Yada T.   +11 more
europepmc   +1 more source